FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy
29 août 2023 16h15 HE
|
FibroGen, Inc.
– Study did not meet the primary endpoint – – Pamrevlumab was generally safe and well tolerated – SAN FRANCISCO, Aug. 29, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced...
FibroGen Reports Second Quarter 2023 Financial Results
07 août 2023 16h01 HE
|
FibroGen, Inc.
Topline data from three late-stage pamrevlumab trials expected through 1H 2024, including the Pancreatic Cancer Action Network (PanCAN) Precision PromiseSM Phase 2/3 study in metastatic pancreatic...
FibroGen Announces Leadership Transition
25 juil. 2023 07h00 HE
|
FibroGen, Inc.
Appoints Thane Wettig as Interim Chief Executive Officer Wettig succeeds Enrique Conterno and brings over 30 years of global pharmaceutical leadership SAN FRANCISCO, July 25, 2023 (GLOBE NEWSWIRE)...
FibroGen to Report Second Quarter 2023 Financial Results
24 juil. 2023 07h00 HE
|
FibroGen, Inc.
SAN FRANCISCO, July 24, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its second quarter 2023 financial results on Monday, August 7 after the market close. FibroGen will also...
FibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis
26 juin 2023 07h04 HE
|
FibroGen, Inc.
- Study did not meet the primary endpoint- Pamrevlumab was generally safe and well tolerated- ZEPHYRUS-2 Phase 3 study will be discontinued- Company to implement plan to extend cash runway into...
FibroGen Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy
07 juin 2023 06h55 HE
|
FibroGen, Inc.
Study did not meet the primary endpointPamrevlumab was generally safe and well tolerated Topline results from LELANTOS-2 Phase 3 study of pamrevlumab in ambulatory patients with DMD expected 3Q 2023 ...
FibroGen to Present at Jefferies Global Healthcare Conference
06 juin 2023 16h01 HE
|
FibroGen, Inc.
SAN FRANCISCO, June 06, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in fireside chats at the following...
FibroGen Announces Positive Topline Results from China Pivotal Phase 3 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia
18 mai 2023 07h30 HE
|
FibroGen, Inc.
Met primary endpoint of noninferiority of roxadustat to erythropoietin alfaPlan to file supplemental New Drug Application in China SAN FRANCISCO and BEIJING, May 18, 2023 (GLOBE NEWSWIRE) --...
FibroGen Reports First Quarter 2023 Financial Results
08 mai 2023 16h01 HE
|
FibroGen, Inc.
• Topline Data From Four Phase 3 Trials Expected Through 3Q 2023 • Completed Non-Dilutive Term Loan Financing for up to $150 Million with Morgan Stanley Tactical Value • Entered Into...
FibroGen Enters into Exclusive License for FOR46 with Fortis Therapeutics
08 mai 2023 16h00 HE
|
FibroGen, Inc.
FOR46, an ADC targeting CD46, is in Phase 1 development with potential applications in mCRPC and other CD46-expressing cancersCollaboration expands FibroGen’s clinical pipeline with potential...